FDA Approves PET Imaging Compound to Aid Early Diagnosis and Disease Monitoring

FDA Approves PET Imaging Compound to Aid Early Diagnosis and Disease Monitoring
The Feinstein Institutes for Medical Research announced that the U.S. Food and Drug Administration (FDA) has approved an imaging compound its researchers developed as a diagnostic tool for people with suspected parkinsonian syndromes, including Parkinson’s disease. Fluorodopa F18 (FDOPA) is an injectable compound used during a PET scan to mark the dopaminergic nerve terminals that degenerate in Parkinson’s disease. Better imaging may increase ... read more
Source: Parkinson’s News TodayPublished on 2020-01-02By Forest Ray